RESUMEN
Oral pemphigoid, defined as cicatricial pemphigoid limited to the oral cavity, is a clinical subset of cicatricial pemphigoid. Like cicatricial pemphigoid, it occurs mostly in middle-aged women and it is uncommon in children under 20 years of age. There are 11 cases of childhood cicatricial pemphigoid published previously in the English language literature, and four of them are oral pemphigoid patients. We present a case of the youngest oral pemphigoid patient reported yet. Because of the rareness of cicatricial pemphigoid in children, delayed diagnosis and treatment have been shown in many cases reported earlier. Clinical awareness and early recognition are, therefore, emphasized.
Asunto(s)
Enfermedades de las Encías/patología , Penfigoide Benigno de la Membrana Mucosa/patología , Niño , Complemento C3/análisis , Diagnóstico Diferencial , Femenino , Técnica del Anticuerpo Fluorescente Directa , Estudios de Seguimiento , Hemorragia Gingival/patología , Gingivitis/patología , Humanos , Inmunoglobulina G/análisisAsunto(s)
Enfermedades de la Boca/etiología , Enfermedades Cutáneas Vesiculoampollosas/complicaciones , Eritema Multiforme/patología , Gingivitis Ulcerosa Necrotizante/patología , Humanos , Inmunoglobulina A/inmunología , Liquen Plano Oral/patología , Lupus Eritematoso Discoide/complicaciones , Enfermedades de la Boca/patología , Enfermedades Cutáneas Vesiculoampollosas/patologíaRESUMEN
The periodontal status of 25 patients with Sjögren's syndrome was compared with that of an age-, sex-, and race-matched healthy controls. Clinical evaluation included determination of number of teeth, decayed/missing/filled surfaces, probing pocket depth, clinical attachment level, plaque index, gingival index, bleeding on probing, and measurement of alveolar bone level (examined with radiography). Results of the study suggest that patients with Sjögren's syndrome have a significantly higher plaque index score (p < 0.005), higher decayed/missing/filled surfaces scores (p < 0.05), increased alveolar bone loss (p < 0.05), deeper clinical attachment level (p < 0.05), and increased cementoenamel junction-alveolar bone crest distance (p < 0.005). Although no significant difference was found in the number of cases of "established periodontitis" between the Sjögren's syndrome and controls, odds ratio analysis suggests that patients with Sjögren's syndrome are at 2.2 times higher risk of having adult periodontitis than healthy controls.
Asunto(s)
Enfermedades Periodontales/etiología , Síndrome de Sjögren/complicaciones , Adulto , Anciano , Anciano de 80 o más Años , Pérdida de Hueso Alveolar/etiología , Estudios de Casos y Controles , Índice CPO , Índice de Placa Dental , Femenino , Humanos , Masculino , Persona de Mediana Edad , Índice Periodontal , Periodontitis/etiología , Prevalencia , Factores de RiesgoAsunto(s)
Liquen Plano Oral/diagnóstico , Enfermedad Crónica , Susceptibilidad a Enfermedades , Femenino , Humanos , Liquen Plano Oral/clasificación , Liquen Plano Oral/etiología , Liquen Plano Oral/patología , Masculino , Persona de Mediana Edad , Boca/patología , Medicina Oral , Factores de Riesgo , Facultades de Odontología , TexasRESUMEN
It has been proposed that healthy gingiva is in a continuous state of wound repair. Thus, one might expect to find cells in normal gingiva producing growth factors associated with wound healing such as platelet-derived growth factor B chain (PDGF-B). One might also expect to find increased numbers of these cells or increased amounts of these growth factors in conditions which involve increased tissue volume such as drug-induced gingival overgrowth (DGO). The purpose of this study was to quantify PDGF-B gene expression and identify cells producing PDGF-B in normal gingiva and DGO. Cyclosporine A (CSA) was selected as a prototype of the overgrowth condition. Twelve patients with clinical CSA DGO and 12 patients with no DGO or history of drugs known to cause DGO were selected for study. Frozen sections of gingival specimens from these patients were subjected to in situ hybridization for PDGF-B mRNA. Positive cells were counted and expressed as mean +/- SEM cells/mm2 of lamina propria. Morphometric analysis revealed 6.2 +/- 1.9 cells/mm2 for control gingiva and 10.3 +/- 3.4 cells/mm2 for CSA DGO samples. There was no statistically significant difference between groups. PDGF-B gene expression was measured in these cells and expressed as mean +/- SEM silver grains/cells. There was a significant upregulation of PDGF-B gene expression in cells from the CSA DGO group (39.5 +/- 14.7 silver grains/cell for normal gingiva vs. 255.3 +/- 77.1 silver grains/cell for CSA DGO samples; P < 0.001). The presence of PDGF-B in these cells was confirmed in all cases by immunocytochemical localization. Additionally, PDGF-B producing cells were identified as macrophages in sections taken from an additional patient with CSA DGO by double immunofluorescence labeling of the CD51 membrane marker for macrophages and intracellular PDGF-B. These findings are consistent with the concept that healthy gingiva is in a continuous state of wound repair and support the hypothesis that CSA DGO is associated with enhanced macrophage PDGF-B gene expression rather than an increase in the number of PDGF-B producing macrophages.
Asunto(s)
Ciclosporina/efectos adversos , Encía/metabolismo , Hiperplasia Gingival/metabolismo , Inmunosupresores/efectos adversos , Factor de Crecimiento Derivado de Plaquetas/metabolismo , Antígenos CD/genética , Antígenos CD/metabolismo , Becaplermina , Colorantes , Técnica del Anticuerpo Fluorescente Directa , Secciones por Congelación , Regulación de la Expresión Génica/efectos de los fármacos , Encía/patología , Hiperplasia Gingival/inducido químicamente , Hiperplasia Gingival/patología , Humanos , Inmunohistoquímica , Hibridación in Situ , Integrina alfaV , Integrinas/genética , Integrinas/metabolismo , Macrófagos/metabolismo , Macrófagos/patología , Factor de Crecimiento Derivado de Plaquetas/genética , Proteínas Proto-Oncogénicas c-sis , Plata , Regulación hacia Arriba/efectos de los fármacos , Regulación hacia Arriba/genética , Cicatrización de Heridas/genéticaRESUMEN
This study investigated the effectiveness of a low-dose cyclosporine rinse used in the treatment of oral erosive lichen planus. Fourteen patients with oral erosive lichen planus provided seven experimental sites treated with cyclosporine and seven control sites treated with a placebo. Participants rinsed with 5 ml (500 mg) of cyclosporine or 5 ml of a placebo for 5 minutes each day over a period of 4 weeks. Cyclosporine blood levels as well as complete blood cell counts with differential and serial multiple analysis were monitored throughout the study. Weekly quantitative measurements of lesion size and character (ulceration, erythema, and reticulation) were recorded with the use of an intraoral grid. Healing was defined as the transition from ulceration to erythema to reticulation or to complete resolution. Pain assessment with the use of a visual analogue scale and a questionnaire pertaining to any side effects of treatment were completed each week. At 4 weeks, a statistically significant difference was observed in lesion healing between the cyclosporine and placebo groups. All experimental sites demonstrated progressive healing with evidence of reduced erythema and ulceration, increased reticulation, and decreased pain scores. In contrast, control sites exhibited minimal change in lesion size or character, and patients reported unchanged or increased pain scores. No significant side effects were reported. Within the parameters of this investigation, topical cyclosporine proved to an effective alternative therapy to currently available medications used in the treatment of oral lichen planus.
Asunto(s)
Ciclosporina/administración & dosificación , Liquen Plano Oral/tratamiento farmacológico , Administración Tópica , Adulto , Anciano , Ciclosporina/uso terapéutico , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Antisépticos Bucales/uso terapéutico , Dimensión del Dolor , Estadísticas no ParamétricasRESUMEN
The field of dental implantology has expanded treatment options available to patients with incomplete dentitions. With the use of regenerative techniques and periodontal plastic surgery procedures, the periodontium and its surrounding tissues can be modified in an attempt to re-create normal function and esthetics. This article describes a combination of surgical procedures, including the placement of endosseous dental implants, guided tissue regeneration, and periodontal plastic surgery, used to restore function and esthetics in the maxillary anterior region.
Asunto(s)
Aumento de la Cresta Alveolar/métodos , Implantación Dental Endoósea , Estética Dental , Periodoncio/cirugía , Adulto , Diente Canino , Femenino , Gingivoplastia , Regeneración Tisular Guiada Periodontal , Humanos , Incisivo , Masculino , Maxilar , Persona de Mediana Edad , Colgajos Quirúrgicos/métodosRESUMEN
At surgery, the results of preoperative radiographic evaluation are used in conjunction with surgical stents to determine the ideal site and angulation of implants. However, it would be desirable to be able to plan the optimal implant location before the actual surgical appointment. This paper presents a technique in which barium-coated stents or dentures are used in conjunction with computer-assisted tomography to locate important anatomic landmarks, such as the inferior alveolar nerve, and anomalies of the underlying bone, such as deficiencies in ridge height, preoperatively. This allows more accurate determination of optimal implant placement.
Asunto(s)
Implantación Dental Endoósea , Planificación de Atención al Paciente , Stents , Tomografía Computarizada por Rayos X/métodos , Anciano , Sulfato de Bario , Humanos , MasculinoRESUMEN
This study was designed to investigate the absorption of a topical steroid applied to the gingiva and buccal mucosa of patients with erosive lichen planus and to healthy control patients. In addition, adrenal suppression was assessed by measurements of serum and urine cortisol levels. Ten patients with erosive lichen planus and eight control patients provided urine and blood samples at baseline, day 3, and day 21. After establishment of baseline laboratory values, patients were instructed to apply 500 mg of a 0.05% fluocinonide gel to the gingiva and buccal mucosa three times a day for 3 weeks. Measurements of cortisol levels revealed no significant changes in either the disease or the control group. Although procedures were developed to detect fluocinonide, none of the patients showed evidence of the steroid during the study. It was concluded that the topical application of a fluocinonide gel to the gingiva and buccal mucosa over a 3-week period in patients with erosive lichen planus produced no adrenal suppression.